Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
---|---|---|---|---|---|---|
Nexavar | Sorafenib tablets | Cancer, Renal cell carcinoma | Do not list | Complete | ||
Rituxan | Rituximab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
Prezista | Darunavir | HIV infection | List with clinical criteria and/or conditions | Complete | ||
Revatio | Sildenafil citrate | Pulmonary arterial hypertension (WHO class II and III) | List in a similar manner | Complete | ||
Cipralex | Escitalopram oxalate | Depression, Major Depressive Disorder (MDD) | Do not list | Complete | ||
Vesicare | Solifenacin succinate | Bladder, overactive | Do not list | Complete | ||
Alvesco | Ciclesonide | asthma | List | Complete | ||
Hepsera | Adefovir dipivoxil | Hepatitis B | Do not list | Complete | ||
NuvaRing | Etonogestrel/ethinyl estradiol | Contraceptive, ring | List with clinical criteria and/or conditions | Complete | ||
Humira | Adalimumab | Arthritis, Psoriatic | List with clinical criteria and/or conditions | Complete |